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INTRODUCTION
In recent years, several tumor-specific shared antigen fam-
ilies, such as melanoma-antigen genes (MAGE), GAGE,
BAGE, and LAGE/NY-ESO-1, which are recognized by auto-
logous cytotoxic T lymphocytes (CTL) have been character-
ized at the molecular level (1, 2). These usually consist of pep-
tides derived from intracellular proteins and are presented
to CTL by HLA class I molecules (3-5). These antigens are
of particular interest in tumor immunology, because their
expression, with an exception of testis and fetal tissues, seems
to be restricted to tumor cells (6). 
The common features of these antigens (4-13) are the pre-
dominant mRNA expression in testis, but generally not in
other normal tissues, the gene activation and high-level
mRNA expression in certain malignancies, and the expres-
sion in malignancies in a lineage-nonspecific manner. An-
other intriguing feature of these antigens is they are mapped
to the X chromosome. These antigens may serve useful targets
for specific immunotherapy, since the expression of MAGE
has not been recognized in normal tissues except for the testis.
Among these, the MAGE gene products are currently under
clinical test as a potential new target for active specific immu-
notherapy (14, 15). In other words, peptides encoded by the
MAGE genes serve targets for specific immunotherapy as they
are presented in association with human leukocyte antigen
class I molecules and are recognized by CTL (3-5). The MAGE
genes comprise more than 4 subfamilies: MAGE-A, B, C, D,
etc (4-13). The MAGE-A genes respresent a family of more
than 12 closely related genes located on the long arm of the
chromosome X (region Xq28) (4, 11, 12). In the majority
of the tumors investigated only the expression of MAGE-A1,
-A2, -A3, -A4, -A6 and -A12 has been mostly shown (4).
However, there is a report that the subfamily MAGE-D was
detected even in normal adult tissues (16). Moreover, a recent
study reported that the cytologic specimens of former smokers
without tumor mass expressed MAGE-A1, -A3, and -B2 (17). 
In recent years, the incidence of colorectal cancer in Korea
has increased to the fifth most prevalent cancer. Therefore, an
appropriate screening method is essential for the early detec-
tion and reduction of the death rate in colorectal cancer. There-
fore we evaluated the feasibility of MAGE common primer
sets as screening method for colorectal cancer. We found 42.1%
of MAGE -A1 to -A6 expression by RT-PCR with common
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Expression of Melanoma Antigen-Encoding Genes (MAGE) by Common
Primers for MAGE-A1 to -A6 in Colorectal Carcinomas Among Koreans
This study was to investigate Melanoma-antigen gene (MAGE) expression by re-
verse transcription-nested polymerase chain reaction (RT-nested PCR) with the
original common primers of MAGE-A1 to -A6 and analysis of correlation between
its expression and the well-known clinical parameters in addition to evaluate the
clinical feasibility of the common primers. Surgical tumor and corresponding non-
neoplastic tissue samples from 38 patients with colorectal cancer were studied.
To confirm the identities of RT-PCR products, direct sequencing was done after
in vitro subcloning. No expression of MAGE was observed in the non-neoplastic
colorectal mucosal tissues. Sixteen (42.1%) of 38 carcinomas expressed at least
one of MAGE A-1 to -6. The expression of the MAGE genes was not related to
age, sex, histological grades, the depth of invasion, metastasis to lymph nodes,
vessel, neural, or perineural invasion. The identities with the corresponding mRNAs
were confirmed in 6 cases for MAGE-A2 (15.8%), 6 cases for MAGE-A4 (15.8%),
2 cases for MAGE-A3 (5.3%), and one case for MAGE A-6 (2.6%). These results
suggest that MAGE expressions, except those of MAGE-A2 and -A4, seem to
have a limited role in the molecular pathogenesis of colon cancer. However, the
common primer sets to detect of expressions for MAGE-A1 to -A6 simultaneously
appear to be feasible to differentiate malignant from benign lesions in colorectal
diseases. 
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primers without any significant relationship with clinical
prognostic markers and also observed that MAGE-A2 and -
A4 were most prevalent in colorectal carcinoma.
MATERIALS AND METHODS
Patients and Clinical Samples
Surgical specimens were obtained from a total of 38 con-
secutive patients with various stages of colorectal carcinoma
who had undergone a surgical resection at the Department
of Surgery of Kosin University Hospital in Pusan (Table 1).
Fresh-frozen primary colorectal carcinoma samples and non-
neoplastic colorectal mucosal tissues 2 cm from the tumor
mass were subjected to mRNA extraction. Their pathologies
were confirmed by frozen section, before mRNA extraction. 
mRNA Isolation
Fresh-frozen colorectal cancer and corresponding non-neo-
plastic colorectal tissue blocks were cut into 4- m sections
using cryostat microtome at -20℃. The first and the last sec-
tions were immediately stained with methylene blue and
examined under a microscope to confirm histologically nor-
mal tissues without tumor cell infiltration and tumor tissue
consisting of at least 80% of tumor cells. Total RNA was iso-
lated from each of the 37 samples after lysis in guanidinium
isothiocyanate and phenol extraction using the commercial
kit (Trizol, Invitrogen Laboratories, San Diego, U.S.A.).
RT-PCR and direct sequencing of PCR products
cDNA was synthesized from 4  g of total RNA in a 25-
L reaction mixture containing 6  L of 5× reverse tran-
scriptase reaction buffer, oligo (dT) (100 pmole/ L) 1  L, 10
mM dNTP 4  L, 40 units/ L of RNAsin, 0.5  L (200 units/
L) of Moloney leukemia virus reverse transcriptase (MMLV
RTase). The mixture was incubated at 42℃for 60 min, heat-
ed to 94℃ for 3 min, and then chilled on ice. To test the
cDNA integrity, GAPDH was amplified for each sample.
To detect the expression of MAGE-A1 to -A6 synchronously
and to avoid amplification of genomic DNA of MAGE, we
designed MAGE common primer sets MC1 sense (CTGAA
GGAGAAGATCTGCC) and MC1 antisense (CTCCAGG
TAGTTTTCCTGCAC) for first round PCR and MC2 sense
(CTGAAGGAGAAGATCTGCCWGTG) and MC2 anti-
sense (CCAGCATTTCTGCCTTTGTGA) for the second
round PCR. These primer sets were designed in such a way
that the 5′ (sense) and 3′ (antisense) primers span at least one
intron in the genomic DNA. That is, each of sense and anti-
sense primers were complementary to two exon sequences
at either side of an intervening intron to prevent hybridiza-
tion to the genomic DNA. These MAGE common primer
pairs were used for the nested PCR of the reverse-transcribed
cDNAs. All oligonucleotide primers were synthesized by and
purchased from the Bioneer Co. (Taejun, Korea). Oligonu-
cleotide primers were solubilized in TE buffer to the con-
centration of 100 pmole/ L, aliquoted, and stored frozen at
-75℃. Each aliquot was diluted to 10 pmole/ L before use.
To ensure that RNA was not degraded, a PCR assay with
primers specific for  -actin cDNA was carried out in each
case, except that only 25 cycles were performed, under the
following cycling conditions: 30 sec at 94℃, 30 sec at 60℃,
and 30 sec at 72℃ with pre-denaturation for 2 min at 94℃
and post-extension at 72℃. A 10- L aliquot of each reaction
mixture was size-fractionated on 1% agarose gel and visual-
ized with ethidium bromide staining. 
Sequencing
Wizard plus SV minipreps kit was used for the template
Age (yrs±SD) 0.098
Mean 58±7.76
<=60 23 7 (30.4)   
>60 15 9 (60.0)
Gender 0.12
Male 18 7 (38.9)
Female 20 9 (45.0)
Histologic grade 0.072
1-2 30 14 (46.7)
3 6 0 (0)   
4 2 2 (100)
Depth of tumor invasion (pT) 0.203
1 2 1 (50.0)
2 6 2 (33.3)
3 26 12 (46.2)
4 4 1 (25.0)
Lymph node metastasis (pN) 0.10
Negative 16 7 (43.8)
Positive 22 9 (40.9)
N1 14 8 (571.)
N2 6 1 (16.7)
Stage 0.073
I 2 1 (50.0)
II 14 6 (42.9)
III 18 8 (44.4)
IV 4 1 (25.0)
Vessel Invasion 0.191
Negative 27 13 (48.1)
Positive 11 3 (27.2)
Perineural invasion  0.169
Negative 32 13 (40.6)
Positive 6 3 (50.0)
Characteristics  p-value
Table 1. Relationship between clinicopathologic characteris-
tics of 38 patients with colorectal carcinoma with mRNA expres-
sion of MAGE genes
No. of patients 
(N=38)
No.of MAGE
positive cases (%)
Pathological diagnoses and staging of colorectal cancer were made
according to the UICC. NS; not-significant statistically (p>0.05).MAGE Expression with Common Primers in Colon Cancer 499
DNA preparation for sequencing after subcloning of RT-PCR
products and Automatic DNA sequencer (in Bukyung Uni-
versity) was used for sequencing. The sequence data were anal-
ysed by the NCBI (NIH, U.S.A.) Blast Search Program.
Statistical Analysis
The statistical analysis was performed using the  2 or Fish-
er's exact test as appropriate. The significance level was set
at p<0.05.
RESULTS
We initially analyzed 38 paired tissue samples of primary
colorectal carcinoma to determine mRNA of the MAGE-A1
to -A6 genes by RT-PCR with the original common primers.
We found 16 (42.1%) of 38 colorectal carcinomas expressed
at least one of MAGE-A1 to -A6 (Fig. 1).
The expression of the MAGE genes was not related to age
or sex (Table 1). There was no significant correlation between
the expression and histological grades (Table 1), the depth of
invasion, metastasis to the lymph nodes (Table 1), vessel and
neural/perineural invasion (Table 1). On the other hand, non-
neoplastic colorectal mucosal tissues did not express mRNA
of MAGE-A1 to -A6 (Fig. 1). 
RT-PCR fragments from each sample were recovered
from gels and sequenced to confirm the identities with the
corresponding mRNAs, and revealed 6 cases of MAGE-A2
(15.8%), 6 cases of MAGE-A4 (15.8%), 2 cases of MAGE-
A3 (5.3%), and one case of MAGE-A6 (2.6%) (Table 2). 
None of the isotypes showed a significant correlation be-
tween its expression and clinicopathological parameters men-
tioned above.
DISCUSSION
Since the notion that the MAGE genes are expressed only
in tumor tissues or tumor cells and are silent in normal tis-
sues, except testis and placenta, has been widely accepted,
some studies have investigated to the feasibility of MAGE
as a tumor marker (1-10). Measuring mRNA was the com-
mon method to evaluate the expression patterns of the MAGE
genes in most of the studies, because there are no commer-
cially available antibodies. Thus, needless to say, the specific
common primer for detecting these gene expressions by RT-
PCR has been required, since the MAGE gene family con-
sists of more than 12 genes and more than 4 subfamilies. Fur-
thermore, there was a report that the subfamily MAGE-D
was detected even in normal adult tissues (16). 
In recent years, the incidence of colorectal cancer in Korea
has increased approaching to the fifth most prevalent cancer.
Therefore, an appropriate screening method has become essen-
tial for the early detection and reduction of the death rate in
colorectal cancer. Therefore we evaluated the feasibility of
MAGE common primer sets as screening method for colorec-
tal cancer. We found 42.1% of MAGE-A1 to -A6 expression.
Previous studies have shown various rates of expression of
the MAGE genes in colorectal carcinoma from 30% to 88%
(18-20) by RT-PCR. Our data seem to be in the middle of
the previous data. This discrepancy may result from different
primer sets and different clinical samples. Even when molecu-
lar biological techniques considered, we have already studied
the MAGE expression in other organs such as head and neck
(21), lung, uterine cervix, and stomach cancers and obtained
results in line with those from others (data not shown) and
also verified our techniques. Further studies on the MAGE
expression in colorectal carcinoma among Koreans are need-
ed to verify the results of this study.
In this study, we did not found any significant relationship
the expression of MAGE to established prognostic markers
by AJCC in colorectal carcinoma. There were two reports that
MAGE, especially MAGE-3 expression was related to meta-
stasis to lymph node or liver (18, 19). However, recently the
study results that tumor stage was inversely related not to
MAGE expression but GAGE expression have been reported
in other gastrointestinal areas (22). The same study revealed
MAGE expression correlated to good prognosis in esophageal
and gastric cancer. This controversy appears to mean heteroge-
nous expression patterns of MAGE as well as necessity of fur-
ther studies to approach the established data. 
One Jananese group (23) reported the expression rates were
7.5% of MAGE-A1, 15.0% of MAGE-A2, 32.5% of MAGE-
A3, 12.5% of MAGE-A4 in colorectal cancer. In our study,
6 cases of MAGE-A2 (15.8%), 6 cases of MAGE-A4 (15.8%),
A2 6 37.5
A4 5 31.25
-4b 1 6.25
A3 2 12.5
A6 1 6.25
Failed 1 6.25
MAGE isotypes No. of positive cases
% in 16 total 
positive cases) 
Table 2. Isotypes of positively detected cases by PCR with
MAGE common primers in 38 cases of colorectal carcinoma
Fig. 1. Electrophoretic analysis of nested RT-PCR amplification
products with common MAGE primers from normal colorectal
mucosa (N) and colorectal cancer (T) of sample No.17-24.
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2 cases of MAGE-A3 (5.3%), and one case of MAGE-A6
(2.6%) were expressed. We observed no distinct co-expres-
sion of the MAGE isotypes in this study. Our results demon-
strated only 2 cases of MAGE-A3 which is considered be the
most promising target for immunotherapy in Koreans in the
light of the HLA type patterns. Therefore, MAGE peptide-
specific immunotherapy might have a limited role in colorec-
tal carcinoma in Korean population. 
Different patterns of the MAGE expressions between pre-
vious results and ours might have resulted from different pri-
mers and different research methods including RT-PCR con-
ditions. We performed RT-PCR first with common primers
and directly sequenced each RT-PCR product after subclon-
ing. However, we followed previous RT-PCR conditions in
the literature. Assessment of the utility of the common primer
sets that we used need further studies.
The functional role of MAGE as well as the exact activa-
tion mechanism has not been well-established yet in colon
cancer. DNA demethylation is widely accepted as the activa-
tion mechanism of MAGE. According to the molecular pro-
gression for the development of colorectal carcinoma (27),
DNA methylation abnormalities may occur in the early stage
(hyperproliferative epithelium). Our results that showed no
relationship between MAGE expression and tumor stages
might be interpreted in the context of the early MAGE ex-
pression during the tumor development. However, there is
no hard evidence that genome-wide methylation abnormal-
ities should be compatible with those of the MAGE genes. 
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